Insulin Lispro

What it is

Insulin lispro is a laboratory-modified copy of human insulin in which two amino acids near the end of the B-chain are swapped, which makes the molecule separate into single units faster after injection and therefore act more quickly than regular human insulin. It is given by injection under the skin or by insulin pump, and in hospital settings intravenously. The FDA label describes it as a rapid acting human insulin analog and records an initial US approval of 1996. It is not a tablet: insulin is a protein and the usual route is subcutaneous injection.

What the research says

The evidence is that insulin lispro lowers blood glucose and, compared with older regular human insulin, produces a slightly lower HbA1c and somewhat fewer hypoglycaemic episodes in type 1 diabetes, but the size of the advantage is small and a 2026 Cochrane network meta-analysis rates much of it as little to no difference with no long-term follow-up data. What is not in doubt is what insulin itself does: it moves glucose out of the blood into muscle and fat and shuts off glucose production by the liver. Its main harm is the direct extension of that action - hypoglycaemia - plus weight gain, lipodystrophy at injection sites and a shift of potassium into cells.

Evidence grade: Well established.

How it works

Drug class: Rapid-acting human insulin analogue (short-acting insulin analogue)

Insulin lispro binds the insulin receptor and does what the body's own insulin does: it pushes glucose out of the bloodstream into muscle and fat, and it stops the liver making new glucose. It also blocks the breakdown of fat and protein. Because of the amino-acid swap it is absorbed faster than regular human insulin, so it is injected close to a meal rather than well before one. (Source 1)

What it is used for

• Approved since 1996 for glycaemic control in diabetes. Against regular human insulin the measured advantage is small: a 2019 meta-analysis in type 1 diabetes found HbA1c lower by about 0.13% and fewer hypoglycaemic episodes, while a 2026 Cochrane network meta-analysis concluded the analogues may make little to no difference to glycaemic control, with no long-term data. Evidence: established. (Source 2)
• Off-label. A 2016 Cochrane review of five small trials (201 participants) found neither advantage nor disadvantage versus intravenous regular insulin for mild or moderate DKA, on mostly low to very low quality evidence. Evidence: limited. (Source 3)

Interactions

• Alcohol (label): Alcohol can push blood glucose either way on top of insulin, so the label groups it with drugs that may increase or decrease insulin's glucose-lowering effect and says dose adjustment and more frequent glucose monitoring may be needed. (Source 4)
• Food and meal timing (label): Insulin lispro is tied to eating: the label directs it to be given within fifteen minutes before a meal or immediately after one, and lists changes in meal pattern - the macronutrient content or timing of meals - among factors that raise the risk of hypoglycaemia. (Source 5)
• Beta-blockers such as propranolol (label): Drugs that block the sympathetic nervous system blunt the early warning signs of a low blood sugar - the racing pulse and tremor - so a hypoglycaemic episode can arrive without warning. This matters directly for anyone taking both insulin lispro and propranolol. (Source 6)
• Potassium-lowering medicines (for example thiazide and loop diuretics) (label): Because insulin drives potassium into cells, people already losing potassium from other medicines can be pushed into hypokalaemia; the label asks for potassium monitoring in that group. (Source 7)

Stopping it

• There is no withdrawal syndrome or dependence with insulin, but in type 1 diabetes it cannot simply be stopped: the disease is an absolute insulin deficiency and without insulin severe hyperglycaemia and diabetic ketoacidosis follow. (Source 8)
• Dose is not fixed and is changed rather than stopped; the label frames dosing as something the prescriber individualises against metabolic needs and glucose monitoring results. (Source 9)

What goes wrong

Hypoglycaemia is the most common harm of insulin lispro and severe episodes can cause seizures or death. (Source 10)

• Official position, High certainty.
• Size: Label summary of the HUMALOG clinical trial programme.
• Who: Adults and children with type 1 or type 2 diabetes using insulin.
• How long: Ongoing treatment.
• Result: The label's Table 1 in adults with type 1 diabetes records severe hypoglycemia in 17% on HUMALOG versus 21% on regular human insulin; in adults with type 2 diabetes 2% versus 2%. These figures are transcribed from a label table and are reported here as numbers, not as a quotation.
• Funding: industry-funded (Eli Lilly trials summarised in the manufacturer's label)

Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Long-term insulin injection can cause lipodystrophy at injection sites, which itself changes how insulin is absorbed. (Source 11)

• Official position, Moderate certainty.
• Size: not stated.
• Who: People using insulin long term.
• How long: Long-term use.
• Result: Frequency not quantified in the label text; described as lipohypertrophy and lipoatrophy that may affect insulin absorption.
• Funding: industry-funded (manufacturer's label)

Long-term use of insulin, including HUMALOG, can cause lipodystrophy at the site of repeated insulin injections or infusion.

Weight gain occurs with insulin including insulin lispro. (Source 12)

• Official position, Moderate certainty.
• Size: not stated.
• Who: People using insulin.
• How long: Ongoing treatment.
• Result: Amount of weight gain not quantified in this label passage.
• Funding: industry-funded (manufacturer's label)

Weight gain can occur with insulins, including HUMALOG, and has been attributed to the anabolic effects of insulin

All insulins shift potassium into cells and untreated hypokalaemia can be fatal. (Source 7)

• Official position, Moderate certainty.
• Size: not stated.
• Who: All insulin users, particularly those on potassium-lowering drugs.
• How long: Any time during treatment.
• Result: Frequency not given; consequences stated as respiratory paralysis, ventricular arrhythmia and death.
• Funding: industry-funded (manufacturer's label)

All insulins, including HUMALOG, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.

What the evidence supports

In type 1 diabetes, short-acting insulin analogues including lispro produced slightly lower HbA1c and fewer hypoglycaemic episodes than regular human insulin. (Source 13)

• Meta-analysis, Moderate certainty.
• Size: up to 6,235 patients across the pooled comparisons.
• Who: People with type 1 diabetes mellitus.
• How long: Trial durations varied; the review pooled short and medium term trials.
• Result: Total hypoglycemic episodes risk rate 0.93 (95% CI 0.87-0.99); nocturnal hypoglycemia 0.55 (0.40-0.76); severe hypoglycemia 0.68 (0.60-0.77); HbA1c mean difference -0.13% (95% CI -0.16 to -0.10). High heterogeneity (I2 up to 84%).
• Funding: not stated.

Short-acting insulin analogues were associated with a decrease in total hypoglycemic episodes (risk rate 0.93, 95% CI 0.87–0.99; 6235 patients; I2 = 81%)

What the evidence does not support

A 2026 Cochrane network meta-analysis concluded that short-acting insulin analogues may make little to no difference to glycaemic control compared with regular human insulin, with no long-term follow-up data. (Source 14)

• Systematic review, Low certainty.
• Size: Network meta-analysis of trials in adults with type 1 diabetes on multiple daily injections.
• Who: Adults with type 1 diabetes mellitus on multiple daily injections.
• How long: Short-term follow-up only; the review states there were no long-term data.
• Result: No numeric advantage for glycaemic control; the review reports uncertainty for nocturnal hypoglycaemia and quality of life.
• Funding: independent (Cochrane)

(Ultra-)short-acting insulin analogues may result in little to no difference in glycaemic control, non-severe hypoglycaemia and treatment adherence at short-term follow-up

Where the evidence is mixed

For mild or moderate diabetic ketoacidosis, subcutaneous rapid-acting insulin analogues showed neither advantage nor disadvantage against intravenous regular insulin, on low to very low quality evidence. (Source 15)

• Systematic review, Very low certainty.
• Size: 201 participants in 5 trials (110 subcutaneous analogue, 91 intravenous regular insulin)
• Who: Mainly adults with mild or moderate diabetic ketoacidosis.
• How long: Until resolution of ketoacidosis and hospital discharge.
• Result: No deaths; time to resolution about 11 hours in both arms; hypoglycaemia 118 per 1000 with intravenous insulin versus 70 per 1000 with subcutaneous insulin lispro, not statistically significant.
• Funding: independent (Cochrane)

Hypoglycaemic (low blood sugar) episodes were comparable: 118 per 1000 participants for intravenous insulin compared with 70 per 1000 participants for subcutaneous insulin lispro (no statistically significant difference).

Where the research disagrees

Whether rapid-acting analogue insulin is meaningfully better than older regular human insulin

• Melo and colleagues, Diabetology & Metabolic Syndrome 2019 meta-analysis, meta-analysis of randomised trials: Short-acting insulin analogues are superior to regular human insulin in T1DM patients for the following outcomes: total hypoglycemic episodes, nocturnal hypoglycemia, severe hypoglycemia, postprandial glucose, and HbA1c. (Source 16)
• Guo and colleagues, Cochrane Database of Systematic Reviews 2026 network meta-analysis, network meta-analysis with certainty grading: (Ultra-)short-acting insulin analogues may result in little to no difference in glycaemic control, non-severe hypoglycaemia and treatment adherence at short-term follow-up (Source 14)

How much

• Reference intake: There is no reference intake for insulin lispro. Dose is set by the prescriber. The FDA label (Eli Lilly, HUMALOG prescribing information as posted on DailyMed) states as a position that the dose is individualised to route of administration, metabolic needs, blood glucose monitoring results and the glycaemic goal, and that it is given within fifteen minutes before a meal or immediately after a meal. (Source 9)
• Upper limit: The HUMALOG label we read sets no numeric maximum daily dose; it gives only the individualisation instruction above. No upper limit is stated as a number in the label sections fetched. (Source 9)
• Studied: In the trials pooled by the 2019 type 1 diabetes meta-analysis, short-acting analogues were compared with regular human insulin in multiple-daily-injection regimens; the review reports outcomes rather than a single fixed dose, because insulin dose is titrated per person. (Source 13)
• Studied: In the diabetic ketoacidosis trials, subcutaneous rapid-acting insulin analogue regimens were compared against intravenous regular insulin infusion in 201 participants with mild or moderate DKA. (Source 15)

A common belief, and what the research shows

The belief: Newer analogue insulins like lispro are clearly much better than older human insulin.

What the research shows: The measured difference is small and the certainty is low. The 2019 meta-analysis found HbA1c lower by about a tenth of a percentage point, and Cochrane's 2026 network meta-analysis concluded that these insulins "may result in little to no difference in glycaemic control, non-severe hypoglycaemia and treatment adherence at short-term follow-up", adding that "There were no long-term follow-up data."

Questions and answers

What is it?

Insulin lispro is a man-made version of human insulin with two amino acids swapped so it is absorbed faster. The FDA label calls it a rapid acting human insulin analog, approved in the United States since 1996 for people with diabetes. It is a protein, so it is injected under the skin or delivered by pump rather than swallowed. (Source 2)

What does it do in the body?

It does what the body's own insulin does. It moves glucose from the blood into muscle and fat, and it stops the liver from making more glucose. It also blocks the breakdown of fat and protein and supports protein building. (Source 1)

Is it good or bad for you?

For someone whose pancreas cannot make enough insulin it is necessary, not optional - type 1 diabetes is an absolute insulin deficiency and without insulin people develop ketoacidosis. The same action that helps is also the main danger: too much insulin, or insulin without the expected food, causes hypoglycaemia, which can cause seizures or death. Whether it is better than older human insulin is a separate and much smaller question, where Cochrane found little to no difference. (Source 10)

How do you get more of it?

Insulin lispro is a prescription medicine, not something obtained from diet or supplements. The usual route into the body is injection under the skin, and the label ties the timing to meals. Dose is set and adjusted by a prescriber, not by the person reading this. (Source 17)

If it is harmful, what reduces it?

The relevant version of this question is what to do when there is too much insulin action, which is hypoglycaemia. The label treats this as a monitoring and education problem rather than something to be neutralised: self-monitoring of blood glucose is described as playing an essential role in preventing and managing it, with more frequent monitoring in people at higher risk or with reduced awareness of lows. (Source 18)

Why might someone be low in it or missing it?

Someone can be short of insulin because the immune system has destroyed the insulin-producing beta cells of the pancreas, which is what type 1 diabetes is. That leaves an absolute deficiency that has to be replaced from outside. In type 2 diabetes the shortfall is relative - insulin is made but works poorly and secretion can fall over time. (Source 19)

Which whole foods contain it or feed it?

No food contains insulin lispro, and insulin cannot be eaten - it is a protein that would be digested, which is why the standard route is subcutaneous injection. Food matters in a different way: the label instructs that the dose be given within fifteen minutes before a meal or immediately after one, and lists changes in the macronutrient content or timing of meals among the things that raise the risk of a low. (Source 5)

What happens if you do not have it?

In type 1 diabetes, going without insulin leads to severe high blood sugar and then diabetic ketoacidosis, which can kill. This is not a gradual decline over years; it develops over hours to days. (Source 8)

How can you test for it?

You do not test for insulin lispro itself in routine care; you test the thing it controls. Diabetes is diagnosed and monitored with plasma glucose measurements and HbA1c, with defined thresholds - fasting plasma glucose of at least 126 mg/dL on more than one occasion, random plasma glucose of at least 200 mg/dL with symptoms, a 2-hour post-load glucose of at least 200 mg/dL, or HbA1c of at least 6.5%. Day-to-day dosing is guided by blood glucose monitoring, which the label describes as essential. (Source 20)

References

1. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use - Full Prescribing Information, section 12.1 Mechanism of Action. 2026. Read the source
2. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Highlights of Prescribing Information, Indications and Usage. 2026. Read the source
3. Cochrane Database of Systematic Reviews (plain language summary page, cochrane.org). Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis - Authors' conclusions. 2016. PMID 26798030, DOI 10.1002/14651858.CD011281.pub2. Read the source
4. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, section 7 Drug Interactions: drugs that may increase or decrease the blood glucose lowering effect. 2026. Read the source
5. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, section 2.2 Administration Instructions for the Approved Routes of Administration. 2026. Read the source
6. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Warnings and Precautions: Hypoglycemia, symptomatic awareness. 2026. Read the source
7. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Warnings and Precautions: Hypokalemia. 2026. Read the source
8. StatPearls Publishing, NCBI Bookshelf. Type 1 Diabetes - StatPearls (Lucier J, Mathias P), consequences of insulin deficiency (sentence printed in the chapter's Continuing Education Activity section, not the clinical body text). 2024. Read the source
9. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, section 2.3 Dosage Recommendations. 2026. Read the source
10. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Warnings and Precautions: Hypoglycemia. 2026. Read the source
11. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Adverse Reactions: Lipodystrophy. 2026. Read the source
12. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Adverse Reactions: Weight gain. 2026. Read the source
13. Diabetology & Metabolic Syndrome. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. 2019. DOI 10.1186/s13098-018-0397-3. Read the source
14. Cochrane Database of Systematic Reviews (plain language summary page, cochrane.org). (Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis - Authors' conclusions. 2026. DOI 10.1002/14651858.CD012161.pub2. Read the source
15. Cochrane Database of Systematic Reviews (plain language summary page, cochrane.org). Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis - Key results. 2016. PMID 26798030, DOI 10.1002/14651858.CD011281.pub2. Read the source
16. Diabetology & Metabolic Syndrome. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis - Conclusions. 2019. DOI 10.1186/s13098-018-0397-3. Read the source
17. StatPearls Publishing, NCBI Bookshelf. Human Insulin - StatPearls (Dave HD, Preuss CV). 2023. Read the source
18. Eli Lilly and Company, via DailyMed (US National Library of Medicine). HUMALOG (insulin lispro) injection - Full Prescribing Information, Risk Mitigation Strategies for Hypoglycemia. 2026. Read the source
19. StatPearls Publishing, NCBI Bookshelf. Type 1 Diabetes - StatPearls (Lucier J, Mathias P). 2024. Read the source
20. StatPearls Publishing, NCBI Bookshelf. Type 1 Diabetes - StatPearls (Lucier J, Mathias P), diagnostic criteria. 2024. Read the source